Revenue Breakdown
Composition ()
No data
Revenue Streams
Bio Rad Laboratories Inc (BIO.B) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Diagnostics, accounting for 59.9% of total sales, equivalent to $391.20M. Another important revenue stream is Life Science. Understanding this composition is critical for investors evaluating how BIO.B navigates market cycles within the its industry.
Profitability & Margins
Evaluating the bottom line, Bio Rad Laboratories Inc maintains a gross margin of 49.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.93%, while the net margin is 103.87%. These profitability ratios, combined with a Return on Equity (ROE) of 10.84%, provide a clear picture of how effectively BIO.B converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BIO.B competes directly with industry leaders such as GKOS and BLCO. With a market capitalization of $7.26B, it holds a leading position in the sector. When comparing efficiency, BIO.B's gross margin of 49.74% stands against GKOS's 77.80% and BLCO's 58.08%. Such benchmarking helps identify whether Bio Rad Laboratories Inc is trading at a premium or discount relative to its financial performance.
